Search - tctmd.com

Displaying 41 - 60 of 92

Sort: Relevancy | Date

Presentation TVT 2017

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Michael J. Reardon

June 16, 2017

Presentation TVT 2017

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

Presenter: David J. Cohen, Mark J. Russo, Adam Castano

June 16, 2017

Presentation TVT 2017

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Presenter: David J. Cohen, Mark J. Russo, Nir Uriel

June 16, 2017

Presentation TVT 2017

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Presenter: David J. Cohen, Mark J. Russo, Ran Kornowski

June 16, 2017

Presentation TVT 2017

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Presenter: David J. Cohen, Mark J. Russo, Suzanne V. Arnold

June 16, 2017

Presentation TVT 2017

Ineffective Endocarditis After TAVR: Cause for Concern?

Presenter: David J. Cohen, Mark J. Russo, Bernard Prendergast

June 16, 2017

Presentation TVT 2017

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Presenter: David J. Cohen, Mark J. Russo, Molly Szerlip

June 16, 2017

Presentation TVT 2017

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

Presenter: Ran Kornowski, Mark J. Russo, David J. Cohen

June 15, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

News Opinion Conversations in Cardiology

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

July 11, 2016

News Conference News TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

Michael O'Riordan

June 20, 2016

Presentation TVT 2016

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

Presenter: David J. Cohen

June 17, 2016

Presentation TVT 2016

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

Presenter: David J. Cohen

June 16, 2016

News Features

当天出院TAVR：反常还是未来的浪潮？

L.A. McKeown

August 27, 2015

News Features

Same-Day TAVR: Anomaly or Wave of the Future?

L.A. McKeown

August 27, 2015

News Daily News

Subanálisis del Ensayo CoreValve norteamericano: Solo la TAVR Femoral Ofrece una Ventaja en la Calidad de Vida Precoz sobre la Cirugía

L.A. McKeown

August 19, 2015

News Daily News

CoreValve美国亚组分析：仅有股动脉TAVR表现出相对于外科手术的早期生活质量优势

L.A. McKeown

August 19, 2015

Advertisement

Spotlight Lecture: The SURTAVI LBCT: CoreValve vs Surgery in Intermediate-Risk Aortic Stenosis Patients

Prevalence of Amyloid in Patients Undergoing TAVR: Low-Flow Phenotype and Echocardiographic Predictors

TAVR to Treat Aortic Regurgitation in LVAD Patients Rationale and Case Examples

Emergent TAVR for AS Patients With Intractable Heart Failure: Feasibility and Early Clinical Results

Who Shouldnt Undergo TAVR? Can We Identify Non-responders?

Ineffective Endocarditis After TAVR: Cause for Concern?

Gender Differences in TAVR Outcomes Recent Analyses in Intermediate-Risk Patients

Optimizing Outcomes of Valve-in-Valve TAVR: The Role of Bioprosthetic Valve Fracture

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Conversations in Cardiology: In the United States, Should TAVR Be Offered to a Low-Risk Patient?

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

New TAVR Risk Models (eg, From TVT and FRANCE 2 Registries): Development, Clinical Validation, Current Use, and Future Directions

Identifying the Futile AS Patient: When Are Extreme Comorbidities Too Much for TAVR?

The Reemergence of Transcarotid TAVR as a Worthwhile Alternative

当天出院TAVR：反常还是未来的浪潮？

Same-Day TAVR: Anomaly or Wave of the Future?

Subanálisis del Ensayo CoreValve norteamericano: Solo la TAVR Femoral Ofrece una Ventaja en la Calidad de Vida Precoz sobre la Cirugía

CoreValve美国亚组分析：仅有股动脉TAVR表现出相对于外科手术的早期生活质量优势

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content